Emerging targets in cancer immunotherapy: Beyond CTLA-4 and PD-1

Immunotherapy

Volumn 7, Issue 11, 2015, Pages 1169-1186

  Assal, Amer ^a   Kaner, Justin ^b   Pendurti, Gopichand ^c   Zang, Xingxing ^b,d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c JACOBI MEDICAL CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

B7 family; checkpoint proteins; immunotherapy; TNFR superfamily; translational medicine

Indexed keywords

B7 ANTIGEN; B7H3 ANTIGEN; CD137 ANTIGEN; CD137 LIGAND; CD27 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; HHLA2 ANTIGEN; LAG 3 PROTEIN; OX40 LIGAND; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROTEIN; TIM 3 PROTEIN; TRYPTOPHAN; UNCLASSIFIED DRUG; URELUMAB; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; VISTA PROTEIN; ANTINEOPLASTIC AGENT; CD223 ANTIGEN; CD274 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR;

CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; META ANALYSIS; METABOLISM; NEOPLASMS; TUMOR ESCAPE;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD274; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR ESCAPE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84948167851     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.78     Document Type: Review

References (145)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331(6024), 1565-1570 (2011).
3. Burnet M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br. Med. J. 1(5023), 841-847 (1957).
4. Dunn GP, Bruce AT, Sheehan KC et al. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 6(7), 722-729 (2005).
5. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960-1964 (2006).
6. Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353(25), 2654-2666 (2005).
7. Taube JM. Emerging immunologic biomarkers: setting the (TNM-immune) stage. Clin. Cancer Res. 20(8), 2023-2025 (2014).
8. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8(6), 467-477 (2008).
9. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc. Natl Acad. Sci. USA 87(13), 5031-5035 (1990).
10. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182(2), 459-465 (1995).
11. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1(5), 405-413 (1994).
12. Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin. Cancer Res. 13(18 Pt 1), 5271-5279 (2007).
13. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256), 1734-1736 (1996).
14. Van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GMCSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190(3), 355-366 (1999).
15. Kwon ED, Foster BA, Hurwitz AA et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4 ) blockade immunotherapy. Proc. Natl Acad. Sci. USA 96(26), 15074-15079 (1999).
16. Hodi FS, O'day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
17. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11(11), 3887-3895 (1992).
18. Agata Y, Kawasaki A, Nishimura H et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8(5), 765-772 (1996).
19. Said EA, Dupuy FP, Trautmann L et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat. Med. 16(4), 452-459 (2010).
20. Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int. Immunol. 10(10), 1563-1572 (1998).
21. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077), 682-687 (2006).
22. Hofmeyer KA, Jeon H, Zang X. The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion. J. Biomed. Biotechnol. 2011, 451694 (2011).
23. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236, 219-242 (2010).
24. Dummer R, Daud A, Puzanov I et al. A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. J. Transl. Med. 13, 2062 (2015).
25. Robert C, Ribas A, Wolchok JD et al. Anti-programmeddeath-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a Phase 1 trial. Lancet 384(9948), 1109-1117 (2014).
26. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010).
27. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
28. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122-133 (2013).
29. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372(4), 311-319 (2015).
30. Lesokhin AM, Ansell SM, Armand P et al. preliminary results of a phase i study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Presented at: 56th ASH Annual Meeting and Exposition. CA, USA, 6-9 December 2014. 31 Weber JS, D'angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol. 16(4), 375-384 (2015).
31. Long GV, Atkinson V, Ascierto PA et al. Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma. J. Transl. Med. 13, 2063 (2015).
32. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373(2), 123-135 (2015).
33. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol. Med. 21(1), 24-33 (2015).
34. Hamid O, Chow LQM, Tavakkoli F et al. Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies. Presented at: 51st Annual Meeting of American Society of Clinical Oncology. IL, USA, 29 May-2 June 2015.
35. Infante JR, Goel S, Tavakkoli F et al. A Phase I, multicenter, open-label, first-in-human study to evaluate MEDI0680, an anti-programmed cell death-1 antibody, in patients with advanced malignancies. Presented at: 51st Annual Meeting of American Society of Clinical Oncology. IL, USA, 29 May-02 June 2015.
36. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5(12), 1365-1369 (1999).
37. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192(7), 1027-1034 (2000).
38. Tsushima F, Yao S, Shin T et al. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 110(1), 180-185 (2007).
39. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111(7), 3635-3643 (2008).
40. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27(1), 111-122 (2007).
41. Park JJ, Omiya R, Matsumura Y et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 116(8), 1291-1298 (2010).
42. Latchman Y, Wood CR, Chernova T et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2(3), 261-268 (2001).
43. Tseng SY, Otsuji M, Gorski K et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193(7), 839-846 (2001).
44. Yamazaki T, Akiba H, Iwai H et al. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 169(10), 5538-5545 (2002).
45. Xiao Y, Yu S, Zhu B et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J. Exp. Med. 211(5), 943-959 (2014).
46. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
47. Beck A, Wurch T, Reichert JM. 6th Annual European Antibody Congress 2010: 29 November-1 December 2010, Geneva, Switzerland. mAbs 3(2), 111-132 (2011).
48. Callahan MK, Ott PA, Odunsi K et al. A Phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. Presented at: 50th Annual Meeting of American Society of Clinical Oncology. IL, USA, 30 May-03 June 2014.
49. Powles T, Vogelzang NJ, Fine GD et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). Presented at: 50th Annual Meeting of American Society of Clinical Oncology. IL, USA, 30 May-03 June 2014.
50. Heery CR, O'sullivan Coyne GH, Madan RA et al. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. Presented at: 50th Annual Meeting of American Society of Clinical Oncology. IL, USA, 30 May-03 June 2014.
51. Tsang K-Y, Boyerinas B, Jochems C et al. Antibody dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody, avelumab (MSB0010718C), on human tumor cells. Presented at: 51st Annual Meeting of American Society of Clinical Oncology. IL, USA, 29 May-2 June 2015.
52. Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc. Natl Acad. Sci. USA 100(18), 10388-10392 (2003).
53. Sica GL, Choi IH, Zhu G et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18(6), 849-861 (2003).
54. Prasad DV, Richards S, Mai XM, Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18(6), 863-873 (2003).
55. Hofmeyer KA, Scandiuzzi L, Ghosh K, Pirofski LA, Zang X. Tissue-expressed B7x affects the immune response to and outcome of lethal pulmonary infection. J. Immunol. 189(6), 3054-3063 (2012).
56. Lee JS, Scandiuzzi L, Ray A et al. B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. J. Immunol. 189(8), 4165-4174 (2012).
57. Wei J, Loke P, Zang X, Allison JP. Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. J. Exp. Med. 208(8), 1683-1694 (2011).
58. Jeon H, Ohaegbulam KC, Abadi YM, Zang X. B7x and myeloid-derived suppressor cells in the tumor microenvironment: a tale of two cities. Oncoimmunology 2(7), e24744 (2013).
59. Zang X, Thompson RH, Al-Ahmadie HA et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc. Natl Acad. Sci. USA 104(49), 19458-19463 (2007).
60. Krambeck AE, Thompson RH, Dong H et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl Acad. Sci. USA 103(27), 10391-10396 (2006).
61. Jiang J, Zhu Y, Wu C et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol. Immunother. 59(11), 1707-1714 (2010).
62. Sun Y, Wang Y, Zhao J et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 53(2), 143-151 (2006).
63. Miyatake T, Tringler B, Liu W et al. B7-H4 (DDO110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol. 106(1), 119-127 (2007).
64. Jeon H, Vigdorovich V, Garrett-Thomson SC et al. Structure and cancer immunotherapy of the B7 family member B7x. Cell Rep. 9(3), 1089-1098 (2014).
65. Zhao R, Chinai JM, Buhl S et al. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc. Natl Acad. Sci. USA 110(24), 9879-9884 (2013).
66. Zhu Y, Yao S, Iliopoulou BP et al. B7-H5 costimulates human T cells via CD28H. Nat. Commun. 4, 2043 (2013).
67. Janakiram M, Chinai JM, Fineberg S et al. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clin. Cancer Res. 21(10), 2359-2366 (2015).
68. Chapoval AI, Ni J, Lau JS et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat. Immunol. 2(3), 269-274 (2001).
69. Suh WK, Gajewska BU, Okada H et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat. Immunol. 4(9), 899-906 (2003).
70. Arigami T, Narita N, Mizuno R et al. B7-H3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann. Surg. 252(6), 1044-1051 (2010).
71. Hofmeyer KA, Ray A, Zang X. The contrasting role of B7-H3. Proc. Natl Acad. Sci. USA 105(30), 10277-10278 (2008).
72. Veenstra RG, Flynn R, Kreymborg K et al. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood 125(21), 3335-3346 (2015).
73. Xylinas E, Robinson BD, Kluth LA et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur. J. Surg. Oncol. 40(1), 121-127 (2014).
74. Zang X, Sullivan PS, Soslow RA et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod. Pathol. 23(8), 1104-1112 (2010).
75. Wang L, Rubinstein R, Lines JL et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 208(3), 577-592 (2011).
76. Lines JL, Pantazi E, Mak J et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 74(7), 1924-1932 (2014).
77. Le Mercier I, Chen W, Lines JL et al. VISTA Regulates the development of protective antitumor immunity. Cancer Res. 74(7), 1933-1944 (2014).
78. Denoeud J, Moser M. Role of CD27/CD70 pathway of activation in immunity and tolerance. J. Leukoc. Biol. 89(2), 195-203 (2011).
79. French RR, Taraban VY, Crowther GR et al. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 109(11), 4810-4815 (2007).
80. Vitale LA, He LZ, Thomas LJ et al. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin. Cancer Res. 18(14), 3812-3821 (2012).
81. Ansell S, Northfelt D, Flinn I et al. A Phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors. J. Immunother. Cancer 1(Suppl. 1), P259-P259 (2013).
82. Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol. Rev. 229(1), 173-191 (2009).
83. Linch SN, Mcnamara MJ, Redmond WL. OX40 Agonists and combination immunotherapy: putting the pedal to the metal. Front Oncol. 5, 34 (2015).
84. Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205(4), 825-839 (2008).
85. National Institues of Health. www.clinicaltrials.gov 87 Curti BD, Kovacsovics-Bankowski M, Morris N et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 73(24), 7189-7198 (2013).
86. Elgueta R, Benson MJ, De Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229(1), 152-172 (2009).
87. Kornbluth RS, Stempniak M, Stone GW. Design of CD40 agonists and their use in growing B cells for cancer immunotherapy. Int. Rev. Immunol. 31(4), 279-288 (2012).
88. Mackey MF, Barth RJ Jr, Noelle RJ. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J. Leukoc. Biol. 63(4), 418-428 (1998).
89. Vonderheide RH, Dutcher JP, Anderson JE et al. Phase I study of recombinant human CD40 ligand in cancer patients. J. Clin. Oncol. 19(13), 3280-3287 (2001).
90. De Vos S, Forero-Torres A, Ansell SM et al. A Phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. J. Hematol. Oncol. 7, 44 (2014).
91. Bensinger W, Maziarz RT, Jagannath S et al. A Phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 159(1), 58-66 (2012).
92. Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Mol. Cancer Ther. 11(5), 1062-1070 (2012).
93. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23, 23-68 (2005).
94. Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat. Rev. Drug Discov. 12(2), 130-146 (2013).
95. Shuford WW, Klussman K, Tritchler DD et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186(1), 47-55 (1997).
96. Narazaki H, Zhu Y, Luo L, Zhu G, Chen L. CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. Blood 115(10), 1941-1948 (2010).
97. Melero I, Shuford WW, Newby SA et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3(6), 682-685 (1997).
98. Palazon A, Teijeira A, Martinez-Forero I et al. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res. 71(3), 801-811 (2011).
99. Aranda F, Vacchelli E, Eggermont A et al. Trial Watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 3(1), e27297 (2014).
100. Li SY, Liu Y. Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. Clin. Pharmacol. 5(Suppl. 1), 47-53 (2013).
101. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin. Oncol. 37(5), 508-516 (2010).
102. Sznol M, Hodi FS, Margolin K et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). Presented at: 44th Annual Meeting of American Society of Clinical Oncology. IL, USA, 30 May-02 June 2008.
103. Kohrt HE, Houot R, Goldstein M et al. CD137 stimulation of natural killer cells to enhance the antilymphoma activity of rituximab. Presented at: 46th Annual Meeting of American Society of Clinical Oncology. IL, USA, 4-8 June 2010.
104. Kohrt HE, Houot R, Weiskopf K et al. Targeting CD137 to enhance the antitumor efficacy of cetuximab by stimulation of innate and adaptive immunity. Presented at: 49th Annual Meeting of American Society of Clinical Oncology. IL, USA, 31 May-4 June 2013.
105. Segal NH, Gopal AK, Bhatia S et al. A Phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer. Presented at: 50th Annual Meeting of American Society of Clinical Oncology. IL, USA, 30 May-03 June 2014.
106. Nocentini G, Giunchi L, Ronchetti S et al. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc. Natl Acad. Sci. USA 94(12), 6216-6221 (1997).
107. Schaer DA, Murphy JT, Wolchok JD. Modulation of GITR for cancer immunotherapy. Curr. Opin. Immunol. 24(2), 217-224 (2012).
108. Schaer DA, Hirschhorn-Cymerman D, Wolchok JD. Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J. Immunother. Cancer 2, 7 (2014).
109. Lu L, Xu X, Zhang B, Zhang R, Ji H, Wang X. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J. Transl. Med. 12, 36 (2014).
110. Pruitt SK, Boczkowski D, De Rosa N et al. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur. J. Immunol. 41(12), 3553-3563 (2011).
111. Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 32(8), 345-349 (2011).
112. Cao E, Zang X, Ramagopal UA et al. T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity 26(3), 311-321 (2007).
113. Grosso JF, Kelleher CC, Harris TJ et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self-and tumor-tolerance systems. J. Clin. Invest. 117(11), 3383-3392 (2007).
114. Macon-Lemaitre L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 115(2), 170-178 (2005).
115. Huang CT, Workman CJ, Flies D et al. Role of LAG-3 in regulatory T cells. Immunity 21(4), 503-513 (2004).
116. Lee CS, Cragg M, Glennie M, Johnson P. Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br. J. Clin. Pharmacol. 76(2), 233-247 (2013).
117. Woo SR, Turnis ME, Goldberg MV et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72(4), 917-927 (2012).
118. Brignone C, Grygar C, Marcu M, Schakel K, Triebel F. A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J. Immunol. 179(6), 4202-4211 (2007).
119. Brignone C, Escudier B, Grygar C, Marcu M, Triebel F. A Phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin. Cancer Res. 15(19), 6225-6231 (2009).
120. Brignone C, Gutierrez M, Mefti F et al. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J. Transl. Med. 8, 71 (2010).
121. Wang-Gillam A, Plambeck-Suess S, Goedegebuure P et al. A Phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest. New Drugs 31(3), 707-713 (2013).
122. Romano E, Michielin O, Voelter V et al. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J. Transl. Med. 12, 97 (2014).
123. Watanabe N, Gavrieli M, Sedy JR et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 4(7), 670-679 (2003).
124. Pasero C, Olive D. Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity. Immunol. Lett. 151(1-2), 71-75 (2013).
125. Karakatsanis S, Bertsias G, Roussou P, Boumpas D. Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant T-lymphoproliferative disorders: brief review. Hematol. Oncol. 32(3), 113-119 (2014).
126. M'hidi H, Thibult ML, Chetaille B et al. High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Am. J. Clin. Pathol. 132(4), 589-596 (2009).
127. Gertner-Dardenne J, Fauriat C, Olive D. BTLA, a key regulator of Vgamma9Vdelta2 T-cell proliferation. Oncoimmunology 2(9), e25853 (2013).
128. Hobo W, Norde WJ, Schaap N et al. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation. J. Immunol. 189(1), 39-49 (2012).
129. Feng XY, Wen XZ, Tan XJ et al. Ectopic expression of B and T lymphocyte attenuator in gastric cancer: a potential independent prognostic factor in patients with gastric cancer. Mol. Med. Rep. 11(1), 658-664 (2015).
130. Fu J, Zhou L, Hong Z, Chen Y, Wang F-S. Association of BTLA upregulation with impaired cytotoxic CD8+ T-cell function and disease progression of patients with hepatocellular carcinoma. Presented at: 50th Annual Meeting of American Society of Clinical Oncology. IL, USA, 30 May-03 June 2014.
131. Derre L, Rivals JP, Jandus C et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J. Clin. Invest. 120(1), 157-167 (2010).
132. Van Baren N, Van Den Eynde BJ. Tryptophan-degrading enzymes in tumoral immune resistance. Front. Immunol. 6, 34 (2015).
133. Theate I, Van Baren N, Pilotte L et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol. Res. 3(2), 161-172 (2015).
134. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin. Cancer Res. 17(22), 6985-6991 (2011).
135. Koblish HK, Hansbury MJ, Bowman KJ et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol. Cancer Ther. 9(2), 489-498 (2010).
136. Uyttenhove C, Pilotte L, Theate I et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9(10), 1269-1274 (2003).
137. Munn DH. Blocking IDO activity to enhance anti-tumor immunity. Front. Biosci. (Elite Ed.) 4, 734-745 (2012).
138. Muller AJ, Duhadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11(3), 312-319 (2005).
139. Khleif S, Munn D, Nyak-Kapoor A et al. First-in-human Phase 1 study of the novel indoleamine-2,3-dioxygenase (IDO) inhibitor NLG-919. Presented at: 50th Annual Meeting of American Society of Clinical Oncology. IL, USA, 30 May-03 June 2014.
140. Kennedy E, Rossi GR, Vahanian NN, Link CJ. Phase 1/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus ipilimumab for the treatment of unresectable stage 3 or 4 melanoma. Presented at: 50th Annual Meeting of American Society of Clinical Oncology. IL, USA, 30 May-03 June 2014.
141. Wolchok JD, Kluger HM, Callahan MK et al. Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). Presented at: 49th Annual Meeting of American Society of Clinical Oncology. IL, USA, 31 May-4 June 2013.
142. Mkrtichyan M, Najjar YG, Raulfs EC et al. Anti-PD-1 synergizes with cyclophosphamide to induce potent antitumor vaccine effects through novel mechanisms. Eur. J. Immunol. 41(10), 2977-2986 (2011).
143. Lorusso PM, Powderly J, Burris HA et al. Abstract LB-193: Phase I study of safety, tolerability, pharmacokinetics, and pharmacodynamics of AMP-224 (B7-DC Fc fusion protein) in a regimen containing cyclophosphamide (CTX) in patients with advanced solid tumors. Cancer Res. 73(8 Suppl.), LB-193-LB-193 (2013).
144. Westin JR, Chu F, Zhang M et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, Phase 2 trial. Lancet Oncol. 15(1), 69-77 (2014).
145. Herbst RS, Gurpide A, Surmont V et al. A Phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer. Presented at: 50th Annual Meeting of American Society of Clinical Oncology. IL, USA, 30 May-03 June 2014.